Experimental brain cancer drug NRG-103 enters first human tests
Disease control
Recruiting now
This early-stage trial tests an experimental drug called NRG-103 in about 24 adults with recurrent or progressive high-grade glioma, an aggressive brain cancer. The main goals are to find a safe dose and check for side effects, while also looking for early signs that the drug mig…
Phase: PHASE1 • Sponsor: Neuregen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC